| Company/Division name | Fujifilm Diosynth Biotechnologies |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 150 |
| What product(s) and/or service(s) were outsourced domestically? | Manufacturing |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2024 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 300 |
| City reshored to: | College Station |
| State(s) reshored to: | TX |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Medical drugs and gene therapies |
| What domestic positive factors made reshoring more attractive? | Government Incentives |
